Search research articles
Contact Us
Filters
Showing results (91-100 of 278) with videos related to
Page
of 28
Sort By:
Kidney International
|
November 6, 2019
Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?
Mark A Perazella, Anushree C Shirali
Expert Opinion on Drug Safety
|
December 19, 2003
Can dual blockade of the renin-angiotensin system reduce progression of kidney disease beyond monotherapy?
Ursula C Brewster, Mark A Perazella
Journal of the American Society of Nephrology : JASN
|
July 1, 2018
Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future
Mark A Perazella, Anushree C Shirali
Kidney360
|
April 4, 2022
Can NSAIDs Be Used Safely for Analgesia in Patients with CKD?: COMMENTARY
Megan L Baker, Mark A Perazella
Kidney360
|
April 4, 2022
The Challenges of Acute Interstitial Nephritis: Time to Standardize
Dennis G Moledina, Mark A Perazella
Seminars in Nephrology
|
December 15, 2010
Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy
Mark A Perazella, Gilbert W Moeckel
The American Journal of the Medical Sciences
|
December 9, 2010
Imaging patients with kidney disease: how do we approach contrast-related toxicity?
Mark A Perazella, Robert F Reilly
American Journal of Nephrology
|
July 16, 2011
Corrigendum regarding the article by Song et al. entitled 'Renal replacement therapy for prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials'
Dinna N Cruz, Mark A Perazella
Clinical Journal of the American Society of Nephrology : CJASN
|
November 19, 2011
Traditional urinary biomarkers in the assessment of hospital-acquired AKI
Mark A Perazella, Steven G Coca
Mayo Clinic Proceedings
|
January 28, 2006
Calcific uremic arteriolopathy (calciphylaxis)
Brian S Rifkin, Mark A Perazella
Page
of 28
Search research articles
Search
Showing results (91-100 of 278) with videos related to
Sort By:
Page
of 28
Kidney International
|
November 6, 2019
Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?
Mark A Perazella, Anushree C Shirali
Expert Opinion on Drug Safety
|
December 19, 2003
Can dual blockade of the renin-angiotensin system reduce progression of kidney disease beyond monotherapy?
Ursula C Brewster, Mark A Perazella
Journal of the American Society of Nephrology : JASN
|
July 1, 2018
Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future
Mark A Perazella, Anushree C Shirali
Kidney360
|
April 4, 2022
Can NSAIDs Be Used Safely for Analgesia in Patients with CKD?: COMMENTARY
Megan L Baker, Mark A Perazella
Kidney360
|
April 4, 2022
The Challenges of Acute Interstitial Nephritis: Time to Standardize
Dennis G Moledina, Mark A Perazella
Seminars in Nephrology
|
December 15, 2010
Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy
Mark A Perazella, Gilbert W Moeckel
The American Journal of the Medical Sciences
|
December 9, 2010
Imaging patients with kidney disease: how do we approach contrast-related toxicity?
Mark A Perazella, Robert F Reilly
American Journal of Nephrology
|
July 16, 2011
Corrigendum regarding the article by Song et al. entitled 'Renal replacement therapy for prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials'
Dinna N Cruz, Mark A Perazella
Clinical Journal of the American Society of Nephrology : CJASN
|
November 19, 2011
Traditional urinary biomarkers in the assessment of hospital-acquired AKI
Mark A Perazella, Steven G Coca
Mayo Clinic Proceedings
|
January 28, 2006
Calcific uremic arteriolopathy (calciphylaxis)
Brian S Rifkin, Mark A Perazella
Page
of 28